Correction to: Vaccine Considerations for Multiple Sclerosis in the COVID-19 Era (Advances in Therapy, (2021), 38, 7, (3550-3588), 10.1007/s12325-021-01761-3)

Patricia K. Coyle, Anne Gocke, Megan Vignos, Scott D. Newsome

Research output: Contribution to journalComment/debatepeer-review

Abstract

The original article was published with an error regarding response to vaccination with ozanimod on page 3561 and in Table 4. The correct sentence and Table 4 are given below The few data available for other S1P receptor modulators suggest there can be some negative impact on vaccine response (145).

Original languageEnglish (US)
Pages (from-to)822-830
Number of pages9
JournalAdvances in Therapy
Volume39
Issue number1
DOIs
StatePublished - Jan 2022

ASJC Scopus subject areas

  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Correction to: Vaccine Considerations for Multiple Sclerosis in the COVID-19 Era (Advances in Therapy, (2021), 38, 7, (3550-3588), 10.1007/s12325-021-01761-3)'. Together they form a unique fingerprint.

Cite this